Treatment of psychosis in elderly people

Psychotic symptoms in elderly people can be seen in a variety of conditions. This article reviews treatment strategies (both pharmacological and non-pharmacological) for such symptoms in schizophrenia and neurodegenerative disorders in this population. Traditionally, antipsychotics have been the most commonly used treatment for psychotic symptoms. Their usefulness in treating schizophrenia, both chronic and late onset, is well established and the atypical antipsychotics, which have a better side-effect profile, are more suitable for elderly people. More recently, there have been increasing concerns about their safety in psychoses due to dementia. The debate about whether an absolute ban on their use is required is still ongoing, but it has highlighted the need for adopting and developing non-pharmacological interventions.

[1]  D. Jeste,et al.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. , 1999, The Journal of clinical psychiatry.

[2]  J. Cohen-Mansfield Nonpharmacologic Interventions for Psychotic Symptoms in Dementia , 2003, Journal of geriatric psychiatry and neurology.

[3]  D. Jeste,et al.  Management of late-life psychosis. , 1996, The Journal of clinical psychiatry.

[4]  R. Scollay Directions For Research And Policy , 2005 .

[5]  S. Lovestone,et al.  Do neuroleptic drugs hasten cognitive decline in dementia? , 1997, BMJ.

[6]  E. Perry,et al.  Neuroleptic sensitivity in patients with senile dementia of Lewy body type. , 1992, BMJ.

[7]  S H Ferris,et al.  Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.

[8]  C. Altar,et al.  Mechanism of Action of Aripiprazole Predicts Clinical Efficacy and a Favourable Side-Effect Profile , 2004, Journal of psychopharmacology.

[9]  R. Howard,et al.  Donepezil for the treatment of psychosis in dementia with Lewy bodies , 2000, International journal of geriatric psychiatry.

[10]  S. Bartels,et al.  Enhanced Skills Training and Health Care Management for Older Persons with Severe Mental Illness , 2004, Community Mental Health Journal.

[11]  L. Schneider,et al.  Meta-Analysis of Controlled Pharmacologic Trials , 1997, International Psychogeriatrics.

[12]  D. Jeste,et al.  Understanding and Managing Psychosis in Late Life , 2003 .

[13]  H. Brodaty,et al.  A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. , 2003, The Journal of clinical psychiatry.

[14]  M F Weiner,et al.  The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. , 1995, The American journal of psychiatry.

[15]  John E. Cooper,et al.  Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR) , 2001, British Journal of Psychiatry.

[16]  J. Lieberman,et al.  Prospective study of tardive dyskinesia in the elderly: rates and risk factors. , 1998, The American journal of psychiatry.

[17]  S. Targum,et al.  Psychoses in the elderly: a spectrum of disorders. , 1999, The Journal of clinical psychiatry.

[18]  T. Macewan,et al.  CSM warning on atypical psychotics and stroke may be detrimental for dementia , 2004, BMJ : British Medical Journal.

[19]  G. Small,et al.  Apolipoprotein E genotype and noncognitive symptoms in Alzheimer’s disease , 1999, Biological Psychiatry.

[20]  V. Lerner,et al.  Successful Use of Donepezil for the Treatment of Psychotic Symptoms in Patients With Parkinson's Disease , 2002, Clinical neuropharmacology.

[21]  A. Morreale,et al.  Drug-induced psychosis and depression in the elderly. , 1988, The Psychiatric clinics of North America.

[22]  R. Lévy,et al.  Which factors affect treatment response in late paraphrenia? , 1992 .

[23]  A. Burns,et al.  The Biology of Psychosis in Older People , 2003, Journal of geriatric psychiatry and neurology.

[24]  S. Kuzuhara Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma , 2001, Journal of Neurology.

[25]  D. Jeste,et al.  Schizophrenia in late life: findings challenge traditional concepts. , 2001, Harvard review of psychiatry.

[26]  G. Grossberg,et al.  The treatment of psychosis in late life. , 1998, The Journal of clinical psychiatry.

[27]  Murat Emre,et al.  Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study , 2000, The Lancet.

[28]  I. Skoog,et al.  Psychotic symptoms and paranoid ideation in a nondemented population-based sample of the very old. , 2002, Archives of general psychiatry.

[29]  S. Zarit,et al.  Subjective burden of husbands and wives as caregivers: a longitudinal study. , 1986, The Gerontologist.

[30]  J. Cummings,et al.  Efficacy of Olanzapine in the Treatment of Psychosis in Dementia with Lewy Bodies , 2002, Dementia and Geriatric Cognitive Disorders.

[31]  Abraham Weizman,et al.  Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy. , 1999, Comprehensive psychiatry.

[32]  J. Frost Paraphrenia and paranoid schizophrenia. , 1969, Psychiatria clinica.

[33]  I. McKeith,et al.  Olanzapine in dementia with Lewy bodies: a clinical study , 1999, International journal of geriatric psychiatry.

[34]  D. Weintraub,et al.  Pharmacologic Management of Psychosis in the Elderly: A Critical Review , 2003, Journal of geriatric psychiatry and neurology.

[35]  F. Post Persistent Persecutory States of the Elderly , 1968 .

[36]  W. L. Ooi,et al.  Evaluation of Simulated Presence: A Personalized Approach to Enhance Well‐Being in Persons with Alzheimer's Disease , 1999, Journal of the American Geriatrics Society.

[37]  C. d’Souza,et al.  MANAGEMENT OF PSYCHOSIS IN PARKINSON'S DISEASE , 2003, International journal of clinical practice.

[38]  R. Tamura,et al.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. , 2000, Archives of general psychiatry.

[39]  J. Morris,et al.  Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) , 1997 .

[40]  J. Friedman,et al.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease , 2002, Biological Psychiatry.

[41]  R. Levy,et al.  Neuropathological Correlates of Psychotic Phenomena in Confirmed Alzheimer's Disease , 1994, British Journal of Psychiatry.

[42]  G. Lenzi,et al.  Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease , 2002, Neurological Sciences.

[43]  C. Lyketsos,et al.  Delusions and hallucinations in Alzheimer's disease: prevalence and clinical correlates , 2000, International journal of geriatric psychiatry.

[44]  G. Dunn,et al.  Cognitive behavioural therapy for drug-resistant psychosis. , 1994, The British journal of medical psychology.

[45]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[46]  D. Jeste Tardive dyskinesia rates with atypical antipsychotics in older adults. , 2004, The Journal of clinical psychiatry.

[47]  L. Schneider,et al.  Quetiapine for Elderly Patients With Psychotic Disorders , 2000 .

[48]  J. Byrne,et al.  What Is Lewy Body Dementia? , 2020, A Caregiver’s Guide to Lewy Body Dementia.

[49]  D. Jeste,et al.  Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. , 2001, The American journal of psychiatry.

[50]  M. Fuller,et al.  Pharmacokinetics of Quetiapine in Elderly Patients with Selected Psychotic Disorders , 2004, Clinical pharmacokinetics.

[51]  G. Grossberg,et al.  Treatment of Late‐onset Psychotic Disorders , 2002 .

[52]  H. Sackeim,et al.  A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. , 1998, The American journal of psychiatry.

[53]  B. Stotsky,et al.  HALOPERIDOL VERSUS THIORIDAZINE FOR HOSPITALIZED PSYCHOGERIATRIC PATIENTS: DOUBLE‐BLIND STUDY * , 1971, Journal of the American Geriatrics Society.

[54]  Jeffrey L. Cummings,et al.  Cholinesterase Inhibitor Therapies and Neuropsychiatric Manifestations of Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[55]  J. Cummings,et al.  Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. , 1999, Archives of neurology.

[56]  Mrc Psych,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop , 1996 .

[57]  I. Katz,et al.  Schizophrenia and older adults. An overview: directions for research and policy. , 2000, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[58]  J. Jankovic,et al.  Olanzapine treatment for dopaminergic‐induced hallucinations , 2002, Movement disorders : official journal of the Movement Disorder Society.

[59]  J. O'Brien,et al.  Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments , 2001, International journal of geriatric psychiatry.

[60]  R. Liberman Psychosocial treatments for schizophrenia. , 1994, Psychiatry.

[61]  E. Wolters,et al.  Intrinsic and extrinsic psychosis in Parkinson's disease , 2001, Journal of Neurology.

[62]  D. Jeste,et al.  Late‐life Psychotic Disorders: Nosology and Classification , 2002 .

[63]  S. Madhusoodanan,et al.  Experience with the Atypical Antipsychotics—Risperidone and Olanzapine in the Elderly , 1999, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[64]  D. Jeste,et al.  Late-Onset Schizophrenia and Very-Late-Onset Schizophrenia-Like Psychosis: An International Consensus , 2000 .

[65]  Principles of Pharmacology , 2003 .

[66]  A. Burns,et al.  Nonpharmacological and pharmacological interventions for symptoms in Alzheimer’s disease , 2004, Expert review of neurotherapeutics.

[67]  S. Targum Treating Psychotic Symptoms in Elderly Patients. , 2001, Primary care companion to the Journal of clinical psychiatry.

[68]  C. Fairburn,et al.  Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up , 1997, BMJ.

[69]  D. Jeste,et al.  Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. , 2000, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[70]  Nir Giladi,et al.  Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease , 2000, Journal of Neural Transmission.

[71]  S. Finkel Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. , 2004, Clinical therapeutics.

[72]  C. Camp,et al.  Prospective memory intervention in Alzheimer's disease. , 1992, Journal of gerontology.

[73]  B. Lawlor,et al.  A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia , 1999, Neurology.

[74]  W. S. Clark,et al.  Long‐term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia , 2001, International journal of geriatric psychiatry.

[75]  A. Burns,et al.  Neuroleptic sensitivity in dementia with cortical Lewy bodies. , 1992, BMJ.

[76]  M. Roth,et al.  Environmental and hereditary factors in the schizophrenias of age ("late paraphrenia") and their bearing on the general problem of causation in schizophrenia. , 1961, The Journal of mental science.

[77]  L. Tune,et al.  Schizophrenia in late life. , 2003, The Psychiatric clinics of North America.

[78]  J. Hare,et al.  Video RespiteM for cognitively impaired persons In nursing homes , 1997 .

[79]  S. Madhusoodanan,et al.  Clinical Experience with Aripiprazole Treatment in Ten Elderly Patients with Schizophrenia or Schizoaffective Disorder: Retrospective Case Studies , 2004, CNS Spectrums.

[80]  J. Mintzer,et al.  Psychosis in Elderly Patients: Classification and Pharmacotherapy , 2003, Journal of geriatric psychiatry and neurology.

[81]  G A Chase,et al.  Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. , 1990, The American journal of psychiatry.

[82]  L. Beckett,et al.  Psychotic Symptoms and Physically Aggressive Behavior in Alzheimer's Disease , 1997, Journal of the American Geriatrics Society.

[83]  E. Granholm,et al.  Development of an integrated cognitive-behavioral and social skills training intervention for older patients with schizophrenia. , 2000, The Journal of psychotherapy practice and research.

[84]  D. Q. Mcmanus,et al.  Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. , 1999, The Journal of clinical psychiatry.

[85]  R. Bullock,et al.  Rivastigmine for the Treatment of Dementia and Visual Hallucinations Associated with Parkinson's Disease: A Case Series , 2002, Current medical research and opinion.

[86]  I. Ferrier,et al.  An evaluation of the predictive validity and inter‐rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type , 1994, Neurology.

[87]  P. Tariot,et al.  Long-Term use of quetiapine in elderly patients with psychotic disorders. , 2000, Clinical therapeutics.

[88]  M. Sajatovic,et al.  Olanzapine therapy in elderly patients with schizophrenia. , 1999, Psychopharmacology bulletin.

[89]  M. Albert,et al.  Predicting time to nursing home care and death in individuals with Alzheimer disease. , 1997, JAMA.

[90]  N. Herrmann,et al.  Atypical antipsychotics and risk of cerebrovascular accidents. , 2004, The American journal of psychiatry.